Benzodioxolylbutanamine

Benzodioxolylbutanamine (BDB), also known as 3,4-methylenedioxy-N-butylamphetamine, is a psychoactive drug and member of the phenethylamine chemical class. It is notable for its entactogenic properties.

History[edit | edit source]

BDB was first synthesized by Alexander Shulgin, a renowned chemist and psychopharmacologist. In his book PiHKAL, Shulgin listed the dosage of BDB as 150–230 mg and the duration as 4–8 hours. He described the effects of BDB as "an alteration of mood, without the forced drive of MDMA".

Pharmacology[edit | edit source]

BDB acts as a serotonin releasing agent (SRA), with a particular focus on the 5-HT1A receptor. It is structurally related to other drugs in the MDxx class, which include MDMA, MDA, and MBDB. However, the effects of BDB are less intense than those of its more famous relatives.

Legal Status[edit | edit source]

The legal status of BDB varies by country. In the United States, it is not explicitly listed as a controlled substance, but it could potentially be considered an analog of MDMA under the Federal Analog Act.

Health Risks[edit | edit source]

As with all psychoactive substances, BDB carries risks. These can include dehydration, hyperthermia, serotonin syndrome, and potential neurotoxicity. It is recommended that users stay hydrated, avoid mixing with other substances, and use harm reduction practices.